» Articles » PMID: 26657898

Activation Loop Phosphorylation Regulates B-Raf in Vivo and Transformation by B-Raf Mutants

Abstract

Despite being mutated in cancer and RASopathies, the role of the activation segment (AS) has not been addressed for B-Raf signaling in vivo. Here, we generated a conditional knock-in mouse allowing the expression of the B-Raf(AVKA) mutant in which the AS phosphoacceptor sites T599 and S602 are replaced by alanine residues. Surprisingly, despite producing a kinase-impaired protein, the Braf(AVKA) allele does not phenocopy the lethality of Braf-knockout or paradoxically acting knock-in alleles. However, Braf(AVKA) mice display abnormalities in the hematopoietic system, a distinct facial morphology, reduced ERK pathway activity in the brain, and an abnormal gait. This phenotype suggests that maximum B-Raf activity is required for the proper development, function, and maintenance of certain cell populations. By establishing conditional murine embryonic fibroblast cultures, we further show that MEK/ERK phosphorylation and the immediate early gene response toward growth factors are impaired in the presence of B-Raf(AVKA). Importantly, alanine substitution of T599/S602 impairs the transformation potential of oncogenic non-V600E B-Raf mutants and a fusion protein, suggesting that blocking their phosphorylation could represent an alternative strategy to ATP-competitive inhibitors.

Citing Articles

Reversible control of kinase signaling through chemical-induced dephosphorylation.

Sun Y, Zhou R, Hu J, Feng S, Hu Q Commun Biol. 2024; 7(1):1073.

PMID: 39217250 PMC: 11366001. DOI: 10.1038/s42003-024-06771-9.


Enzyme Is the Name-Adapter Is the Game.

Huber M, Brummer T Cells. 2024; 13(15.

PMID: 39120280 PMC: 11311582. DOI: 10.3390/cells13151249.


MOST wanted: navigating the MAPK-OIS-SASP-tumor microenvironment axis in primary pediatric low-grade glioma and preclinical models.

Sigaud R, Brummer T, Kocher D, Milde T, Selt F Childs Nerv Syst. 2024; 40(10):3209-3221.

PMID: 38789691 PMC: 11511703. DOI: 10.1007/s00381-024-06463-z.


A review on potential heterocycles for the treatment of glioblastoma targeting receptor tyrosine kinases.

Bhusare N, Kumar M Oncol Res. 2024; 32(5):849-875.

PMID: 38686058 PMC: 11055995. DOI: 10.32604/or.2024.047042.


DNA Sequencing of CD138 Cell Population Reveals TP53 and RAS-MAPK Mutations in Multiple Myeloma at Diagnosis.

Dragomir M, Calugaru O, Popescu B, Jardan C, Jardan D, Popescu M Cancers (Basel). 2024; 16(2).

PMID: 38254847 PMC: 10813921. DOI: 10.3390/cancers16020358.


References
1.
Kohler M, Roring M, Schorch B, Heilmann K, Stickel N, Fiala G . Activation loop phosphorylation regulates B-Raf in vivo and transformation by B-Raf mutants. EMBO J. 2015; 35(2):143-61. PMC: 4718462. DOI: 10.15252/embj.201592097. View

2.
Samatar A, Poulikakos P . Targeting RAS-ERK signalling in cancer: promises and challenges. Nat Rev Drug Discov. 2014; 13(12):928-42. DOI: 10.1038/nrd4281. View

3.
Barnier J, Papin C, Eychene A, Lecoq O, Calothy G . The mouse B-raf gene encodes multiple protein isoforms with tissue-specific expression. J Biol Chem. 1995; 270(40):23381-9. DOI: 10.1074/jbc.270.40.23381. View

4.
Barnard D, Diaz B, Clawson D, Marshall M . Oncogenes, growth factors and phorbol esters regulate Raf-1 through common mechanisms. Oncogene. 1998; 17(12):1539-47. DOI: 10.1038/sj.onc.1202061. View

5.
Cin H, Meyer C, Herr R, Janzarik W, Lambert S, Jones D . Oncogenic FAM131B-BRAF fusion resulting from 7q34 deletion comprises an alternative mechanism of MAPK pathway activation in pilocytic astrocytoma. Acta Neuropathol. 2011; 121(6):763-74. DOI: 10.1007/s00401-011-0817-z. View